Effect and safety on carteorol for infantile hemangioma

Effect and safety on carteorol for infantile hemangioma - Effect and safety on carteorol for infantile hemangioma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029988

Enrollment

Registered

2018-01-01

Start date

2018-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infantile hemangioma

Interventions

Oral administartion of carteorol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Proliferating infantile hemangioma over 1.5cm 2 informed consent

Exclusion criteria

Exclusion criteria: 1 congenital hemangioma, Kasabah-Merritt syndrome 2 hypoglycemia, hypotension, bradycardia (arrhythmia), cardiac function disorder 3 Otehr drug administaraion interacted with carteorol within 14 days 4 history of other therapy foy infantile hemangioma(steroid therapy, laser therapy etc)

Design outcomes

Primary

Measure	Time frame
Availability of carteorol therpy after 24weeks administration	—

Secondary

Measure	Time frame
Hemangioma size, color and shape after 24weeks administration	—

Countries

Japan

Contacts

Public ContactTakamichi Uchiyama

Takatsuki General Hospital Department of Pediatrics

uchiyama@ajk.takatsuki-hp.or.jp072-681-3801

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026